1. Breast Cancer Research Report SWAG Site Specific Group
Clinical Research Network
West of England
Breast Cancer Research Report SWAG Site Specific Group
Friday 1st July 2016
Maxine Taylor
Senior Research Delivery Manager - Cancer

2. South West Research Networks & SWAG
West of England
SWAG
South West Peninsula

3. Local Clinical Research Networks
Translation of national objectives for clinical research
Oversight of research activity within the geography of CRN - West of England in terms of:
Portfolio
Balance, new studies, feasibility, industry trials
Performance
Support, network wide solutions, targets
People
Patient involvement, staff skill mix & flexibility, training, resources

4. National objectives Timely set up of studies
Recruitment to time and target
Include commercial research

5. Objectives for cancer Recruit 20% of cancer incidence
Recruit 7.5% of cancer incidence into interventional studies
Include challenging studies
Children and TYA cancers
Rare cancers
Surgical studies
Radiotherapy studies

6. National recruitment to breast cancer studies by local network 2015-16

8. Recruiting studies

10. Recruiting studies 2016-17 StudyDesignType Short Name
GREAT WESTERN HOSPITALS NHS FOUNDATION TRUST
NORTH BRISTOL NHS TRUST
ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST
TAUNTON AND SOMERSET NHS FOUNDATION TRUST
UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST
WESTON AREA HEALTH NHS TRUST
YEOVIL DISTRICT HOSPITAL NHS FOUNDATION TRUST
Grand Total
Both
MAMMO-50 1 6 2 12
Both Total
Interventional
A multi-centred-study of the effectiveness of PEGASUS 7
CONCEPT (Breast Cancer)
FURVA, Version 1.0 3 5 8
MANTA
NCRN
POSNOC
ROSCO
Interventional Total 4 31
Observational
CANC MBC - disease registry study
Chemo-NEAR
Observational Total 9 15 45

11. Viewing the portfolio http://csg.ncri.org.uk/portfolio/portfolio-maps/
IBIS 3 An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment
Baronet Biological and radiological outcomes of neoadjuvant endocrine treatment
BLUEBELL A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy

12. Contacts West of England
Breast cancer (oncology) specialty lead –
Breast cancer (surgery) specialty lead –
Research Delivery Manager –
Cancer portfolio facilitator –
South West Peninsula
Breast cancer specialty lead –
Cancer Research Delivery Manager -